Mixed-Cancer Populations
| Study | Design | Patients (n) | PET/MRI | Indication | T-staging | N-staging | M-staging | Superiority |
| Drzezga (85) | Prospective | 32 | Simultaneous | Staging, restaging | NS | NS | NS | ND |
| Quick (86) | Prospective | 80 | Simultaneous | Staging, restaging | — | — | — | ND |
| Al-Nabhani (87) | Prospective | 50 | Simultaneous | Staging | — | — | — | NS |
| Catalano (88) | Retrospective | 134 | Simultaneous | Staging, restaging | — | — | — | PET/MRI superior for patient management (P < 0.001) |
| Wiesmuller (89) | Prospective | 46 | Simultaneous | Staging, restaging | — | — | — | ND |
| Appenzeller (90) | Prospective | 63 | Sequential | Staging, restaging | — | — | — | ND |
| Jeong (91) | Not stated | 12 | Simultaneous | Staging, restaging | — | — | — | ND |
| Huellner (92) | Prospective | 106 | Sequential | Staging, restaging | NS | NS | NS | ND (more incidental findings by PET/CT) |
| Schäfer (83) | Prospective | 18 | Simultaneous | Staging, restaging | — | — | — | ND |
| Iagaru (10) | Prospective | 36 | Simultaneous | Staging, restaging | — | — | — | ND |
| Tian (93) | Retrospective | 285 | Simultaneous | Staging, restaging | — | — | — | ND |
| Heusch (94) | Retrospective | 73 | Simultaneous | Staging | NS | NS | ND | ND |
| Schaarschmidt (95) | Retrospective | 61 | Simultaneous | Staging | NS | NS | NS | ND |
| Total | 996 |
NS = nonsignificant; ND = no difference; — = not reported.